Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-13T02:31:29.919Z Has data issue: false hasContentIssue false
  • English
  • Français

Intravenous sotalol use in a complex critically ill child: balancing the systems in choosing antiarrhythmic medication

Published online by Cambridge University Press:  11 August 2017

Michele M. Pasierb Open the ORCID record for Michele M. Pasierb [Opens in a new window]  and
Stephen P. Seslar
Michele M. Pasierb
Affiliation:
Division of Pediatric Cardiology, University of Washington School of Medicine, Seattle Children’s Hospital, Seattle, Washington, United States of America
Stephen P. Seslar*
Affiliation:
Division of Pediatric Cardiology, University of Washington School of Medicine, Seattle Children’s Hospital, Seattle, Washington, United States of America
*
Correspondence to: S. P. Seslar, MD, Division of Pediatric Cardiology, Seattle Children’s Hospital, 4800 Sand Point Way NE, RC.2.820, PO Box 5371, Seattle, WA 98145, United States of America. Tel: 206 987 5646; Fax: 206 987 3839; E-mail: Stephen.Seslar@seattlechildrens.org
Get access Rights & Permissions [Opens in a new window]

Abstract

In critically ill children, multi-organ-system disease can influence the choice of antiarrhythmic medication. Intravenous therapy is often necessary. There is a scarcity of paediatric critical-care cases demonstrating the dosing, monitoring, and efficacy of intravenous sotalol. This case demonstrates the effective use of intravenous sotalol in an adolescent with renal, hepatic, and haematological dysfunctions.

Keywords

Sotalolpaediatric critical careatrial flutteratrial fibrillationintravenous
Type
Brief Report
Information
Cardiology in the Young , Volume 27 , Issue 9 , November 2017 , pp. 1857 - 1860
Check for updates
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Kpaeyeh, JA, Wharton, JM. Sotalol. Card Electrophysiol Clin 2016; 8: 437–452.CrossRefGoogle ScholarPubMed
2. Blair, AD, Burgess, ED, Maxwell, BM, et al. Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther 1981; 29: 457–463.Google Scholar
3. Somberg, JC, Preston, RA, Ranade, V, et al. Developing a safe intravenous sotalol dosing regimen. Am J Ther 2010; 17: 365–372.CrossRefGoogle ScholarPubMed
4. Hanyok, JJ. Clinical pharmacokinetics for sotalol. Am J Cardiol 1993; 72: 19A–26A.Google Scholar
5. Pfammatter, JP, Paul, T. New antiarrhythmic drug in pediatric use: sotalol. Pediatr Cardiol. 1997; 18: 28–34.CrossRefGoogle ScholarPubMed
6. Tjandramaga, TB, Verbeeck, R, Thomas, J, et al. The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol 1976; 3: 259–265.CrossRefGoogle ScholarPubMed
7. Danielly, J, DeJong, R, Radke-Mitchell, LC, et al. Procainamide-associated blood dyscrasias. Am J of Cardiology 1994; 74: 1179–1180.Google Scholar